ATYR
aTyr Pharma, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-05
Figures on this page computed 2026-11-08 12:40 UTC
Last close
6.03USD
Market data, 2026-11-05
Except where said otherwise: 10-K for 2025, filed 2026-03-05
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-05
-112.9%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-07
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-07
-39009.5%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
-32664.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
0.18Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-07
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Growth is the furthest below its sector's middle: 0.19 against 0.50 on the market's range.
- Growth-55.1%19 of 100, below its sector
- Returns on capital-112.9%7 of 100, below its sector
- Margins-40856.3%0 of 100, below its sector
- Price0.2x47 of 100, above its sector
- Safety0.1854 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
5 of 5 readExcept where said otherwise: 10-K for 2025, filed 2026-03-05
- Sales0.06x
Its own average over 7 years, 3.1M.
- Profit1.68x
Its own average over 10 years, -44.1M.
- Free cash flow1.51x
Its own average over 10 years, -41.0M.
- Debt1.04x
Its own average over 10 years, 11.6M.
- Price0.07x
Its own average over 3 years, 84. Market data, 2026-11-05
Sales is furthest from its own average, at 0.06 times.
Sales is 0.06 times its own 7-year average; Profit is 1.68 times its own 10-year average; Free cash flow is 1.51 times its own 10-year average; Debt is 1.04 times its own 10-year average; Price is 0.07 times its own 3-year average.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-05
Sales against its own 7-year average0.06
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
Profit against its own 10-year average1.68
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
Free cash flow against its own 10-year average1.51
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
Debt against its own 10-year average1.04
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001339970-26-000008
- Reported in
- USD
Price against its own 3-year average0.07Market data, 2026-11-05
- Source
- market
- Taken on
- 2026-11-05
- Reported in
- USD